Passage Bio Inc (PASG)

NASDAQ

$4.81

Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company is headquartered in Philadelphia, Pennsylvania.

Website: https://www.passagebio.com

Sector:

Healthcare

Industry:

Biotechnology

68 analysts

Buy

Target: $15.50 (+222.25%)

Market Cap

$16M

Beta (5Y)

2.00

Price Chart

Adjust inflation

Log

Valuation

Market Cap$16M

P/B1.21

Profitability

EBITDA-$40M

EPS-$11.83

Growth & Risk

EPS 5Y CAGR-26.73%

FCF 5Y CAGR-19.27%

Beta (5Y)2.00

Sharpe Ratio0.44